Consequently, one can extrapolate from the studies performed thus far that targeting platelet NF-κB, as demonstrated with cellular NF-κB, might confer a plethora of therapeutic benefits first at the level of platelet survival, priming, activation, and aggregation and second in the context of atherothrombotic coronary artery diseases. Here, NFKB1 is linked to coronary artery disorder.